ADVERTISEMENT
Updated
blue and white sign for the entrance to the FDA that says U.S. Department of Health and Human Services Food and Drug Administration
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews

A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

drug development, FDA, disease & medicine

Opinion: Emergency Use Authorizations Are a Threat to Science 
Kevin J. Tracey and Christina Brennan | Dec 1, 2020 | 4 min read
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
Jef Akst | Oct 8, 2020 | 9 min read
Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.
a bag of plasma ready to be delivered by IV
Doctors Forge Ahead with Plasma for COVID-19, Benefits Uncertain
Shawna Williams | Aug 14, 2020 | 2 min read
Researchers say the popularity of convalescent plasma makes it more difficult to gather high-quality data on its efficacy.
Activities Discovered for Some Inactive Drug Ingredients
Ruth Williams | Jul 23, 2020 | 4 min read
Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.
First New Tuberculosis Drug Approved in 50 Years
Jef Akst | Aug 15, 2019 | 2 min read
The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.
New Treatments for Phenylketonuria Aim to Loosen Reins on Strict Diet
Diana Kwon | May 29, 2018 | 5 min read
Biotechs have developed enzyme replacements and genetically modified probiotics to treat patients with the rare metabolic disorder.
ADVERTISEMENT